Posted inOPINION

Foreign drug pricing models leave patients – and economic growth – behind

Kirsten Axelsen argues that adopting foreign-style drug pricing models in the United States would harm patients and stifle innovation. While other nations keep prices low by denying access through health technology assessments and rigid cost-effectiveness thresholds, the U.S. system fosters competition, broad access, and generics that lower costs. She contends the U.S. should push for fairer global cost-sharing rather than importing restrictive foreign policies.

Gift this article